Retatrutide UK: The Definitive Guide to Evidence, Availability, Risks & Alternatives

Retatrutide UK status: the most important fact first

This guide therefore treats retatrutide differently from Mounjaro or Wegovy. We can discuss the evidence, the possible future role and how it compares with current treatments — but we will not pretend it is something you can safely shop around for today.

What is retatrutide?

Retatrutide, also known by the development code LY3437943, is an investigational once-weekly injectable medicine being developed by Eli Lilly for obesity and related metabolic conditions.

It has attracted enormous attention because it acts on three hormone receptors rather than one or two:

This is why retatrutide is often described as a triple agonist. Wegovy acts primarily through GLP-1. Mounjaro acts through GIP and GLP-1. Retatrutide adds glucagon-receptor activity to those two pathways.

How might a triple agonist work differently?

The goal is not simply to suppress appetite harder. The three receptor pathways influence several parts of metabolic regulation. GLP-1 and GIP can support appetite reduction and glucose-dependent insulin signalling, while glucagon-receptor activity may influence energy expenditure and fat metabolism.

The important word is may. A plausible mechanism does not guarantee better long-term outcomes or fewer side effects. Clinical trials are what tell us whether the theoretical benefit translates into meaningful outcomes for real patients.

What does the Phase 3 evidence show so far?

Retatrutide moved from promising Phase 2 data into a large Phase 3 programme called TRIUMPH. In May 2026, Lilly reported topline results from TRIUMPH-1, a pivotal Phase 3 obesity study. At 80 weeks, participants taking the highest 12 mg dose lost an average of around 28.3% of body weight under the efficacy estimand, and 45.3% of participants at that dose achieved at least 30% weight reduction.

Lilly subsequently presented an extension in which participants continuing to 104 weeks lost up to an average of around 30% of their starting body weight at the highest dose.

In July 2026, Lilly also reported Phase 3 TRIUMPH-2 results in adults with obesity or overweight and type 2 diabetes, where participants lost up to an average of 20.8% at 80 weeks.

The TRIUMPH clinical-trial programme

Retatrutide is being studied across obesity and several obesity-related complications rather than in one isolated weight-loss trial.

Some important trials are still ongoing into 2027–2028 and beyond. That is why “we know everything already” would be nonsense.

How much weight could retatrutide eventually help people lose?

The current Phase 3 headline numbers are unprecedented for a non-surgical obesity medicine, but the sensible way to interpret them is in ranges rather than guarantees.

If somebody starts at 20 stone, 30% is mathematically 6 stone. That does not mean “retatrutide makes you lose six stone”. It means a 30% trial average would be equivalent to six stone at that particular starting weight. Real people sit above and below trial averages.

Side effects and safety: what do we know?

Gastrointestinal side effects remain an important part of the picture, as with existing incretin medicines. Phase 3 reports describe nausea, diarrhoea, vomiting and constipation among the common adverse events, particularly during dose escalation.

The full long-term safety profile is still developing. That matters because an obesity treatment may be used for years, not weeks. Regulators will look at adverse events, discontinuation rates, gallbladder and pancreatic safety, cardiovascular outcomes, metabolic effects and other signals across the development programme.

It is also possible that future approved labelling, contraindications, pregnancy advice and dose-escalation schedules will differ from what people currently assume based on trial protocols.

The grey-market problem: why online retatrutide is a different proposition

The risks are not theoretical:

• You cannot assume the vial contains retatrutide.
• You cannot assume the stated dose is correct.
• You cannot assume it is sterile.
• You cannot assume it has been stored correctly.
• You may have no legitimate prescriber monitoring you.
• You may have no pharmacovigilance or proper route if something goes wrong.

Calling something “research grade” does not turn self-injection into a clinical trial. Authorised clinical trials have protocols, investigators, ethics approval, manufacturing standards, monitoring and adverse-event reporting.

How much does retatrutide cost in the UK?

There is no legitimate routine UK retail price for approved retatrutide obesity treatment because there is no approved UK retatrutide product.

Any website currently advertising a “retatrutide price” is therefore not giving you the cost of an MHRA-authorised retatrutide weight-management medicine. It is offering an unlicensed or potentially illicit product.

If retatrutide is eventually authorised, private pricing will depend on the manufacturer, dose, provider, prescribing service, market competition and supply. NHS cost-effectiveness would be a separate NICE question.

Will retatrutide be available on the NHS?

There is currently no NHS retatrutide obesity pathway because the medicine is not authorised for UK use. Even after any future MHRA authorisation, NHS availability would normally require the relevant health-technology assessment and commissioning decisions.

Mounjaro is a useful example of why these are separate stages: UK marketing authorisation does not mean universal NHS access on day one. NHS eligibility can be narrower, prioritised and phased.

So when somebody online says “retatrutide will be on the NHS next year”, treat that as speculation unless it is backed by actual MHRA/NICE/NHS announcements.

When will retatrutide actually be available?

There is no confirmed routine UK launch date we can responsibly give you today.

The development programme has progressed quickly, and pivotal Phase 3 data now exist, but availability depends on regulatory submissions, review, approval, manufacturing, launch decisions and — separately — NHS assessment.

Some Phase 3 and Phase 3b studies continue into 2027–2028, including direct comparison with tirzepatide and different dose-escalation strategies.

Retatrutide vs Mounjaro: what can we genuinely say?

If treatment is appropriate today, Mounjaro has the enormous practical advantage of actually being an authorised medicine. Retatrutide's headline trial numbers do not turn an unapproved drug into a current alternative.

Retatrutide vs Wegovy

Wegovy (semaglutide) is a GLP-1 receptor agonist already authorised for weight management in the UK. Retatrutide adds GIP and glucagon activity and has produced larger headline weight-loss figures in separate trials.

But separate trials are not a clean head-to-head comparison. Differences in study populations, analysis methods, trial duration, treatment protocols and participant characteristics all matter.

Wegovy also has a much more mature regulatory and real-world evidence base today. Retatrutide may eventually become a powerful option, but “newer and bigger number” is not the same as “right choice for me”.

Could retatrutide replace bariatric surgery?

Probably not as a simple either/or question. Retatrutide's Phase 3 weight-loss magnitude has entered territory historically associated with bariatric procedures for some patients, which is scientifically important. But surgery and medication are fundamentally different interventions.

Surgery has procedural risk, recovery and lifelong nutritional implications, but it also has decades of outcome data. Medication avoids an operation but may require ongoing treatment, tolerability, affordability and long-term adherence.

For somebody with severe obesity, the future question may increasingly become which tool, in which sequence, for which person? rather than “drug or surgery forever”.

Should I wait for retatrutide instead of starting Mounjaro or Wegovy?

Usually, this is the wrong way to frame the decision.

A future medicine can be revisited when it is actually approved, has a real UK label and can be prescribed safely.

What can I choose today instead?

Compare current medicines →

Don't want to wait for another drug? Start the free route now

You can make meaningful changes while the science moves on.

Questions you probably haven't thought to ask yet

• If retatrutide is eventually approved, how long might I need to stay on it?
• Will NHS access be much narrower than the licence?
• What if my current treatment is already working well?
• Would switching for an extra few percentage points actually improve my health?
• Will retatrutide preserve muscle any better?
• What will happen when treatment stops?
• Could more receptor activity create new trade-offs?
• What will the approved titration schedule actually be?
• What will long-term cardiovascular data show?
• Will it be appropriate for people who previously could not tolerate GLP-1 medicines?
• How will it compare directly with tirzepatide, not indirectly across trials?
• What will it cost privately?
• Would surgery still make more sense in severe obesity?
• If I buy a grey-market product now, who looks after me if something goes wrong?

Retatrutide FAQs

Is retatrutide available in the UK?

No. As of 8 August 2026, retatrutide is not authorised for routine UK use.

Can I buy retatrutide online?

Products are being advertised online, but that does not make them authorised UK medicines. MHRA has specifically warned against illegal unlicensed retatrutide products.

Is retatrutide a GLP-1?

It includes GLP-1 receptor activity but also targets GIP and glucagon receptors, making it a triple agonist.

Who makes retatrutide?

Retatrutide is being developed by Eli Lilly and Company.

How much weight was lost in Phase 3?

Lilly reported around 28.3% average weight reduction at 80 weeks at the highest dose in TRIUMPH-1 under the efficacy estimand, with extension data approaching 30% at 104 weeks.

Is retatrutide better than Mounjaro?

We do not yet have a complete routine clinical answer. A direct Phase 3 retatrutide-vs-tirzepatide study is underway.

Is it stronger than Wegovy?

Separate-trial headline weight loss is larger, but separate trials are not a fair head-to-head comparison and retatrutide is not yet authorised.

When will it launch?

There is no confirmed routine UK launch date that can responsibly be stated today.

Will it be on the NHS?

There is no current NHS pathway. Future NHS use would depend on authorisation and subsequent health-technology and commissioning decisions.

How much will it cost?

There is no legitimate approved UK retail price yet.

Can I join a trial?

Some retatrutide studies are ongoing. Eligibility and locations are determined by each authorised trial; use official clinical-trial registries rather than sellers.

What are the side effects?

Gastrointestinal effects such as nausea, diarrhoea, vomiting and constipation have been reported commonly in trials; the complete long-term safety profile continues to develop.

Should I wait for it?

If your health requires treatment now, do not delay appropriate evidence-based care solely because a future medicine looks promising.

Can I use research peptides instead?

Self-sourcing unlicensed 'research' retatrutide is not equivalent to participating in a regulated clinical trial and carries significant quality and safety risks.

Could it replace surgery?

It may change future treatment decisions, but surgery and medication have different risks, durability, evidence and long-term implications.

Shift Says

Printable decision summary

Sources & further reading

We use regulator, clinical-trial registry and manufacturer trial sources here because retatrutide is an evolving investigational treatment. Status can change, so this page should be reviewed whenever major regulatory or Phase 3 developments occur.

• MHRA – No summer shortcut for safe weight loss (24 July 2026)
• ClinicalTrials.gov – Retatrutide obesity + knee osteoarthritis Phase 3
• ClinicalTrials.gov – Retatrutide vs tirzepatide Phase 3
• ClinicalTrials.gov – Retatrutide cardiovascular outcomes study
• ClinicalTrials.gov – Retatrutide dose-escalation Phase 3b
• Lilly – TRIUMPH-1 Phase 3 topline results
• Lilly – TRIUMPH-2 Phase 3 results
• Lilly – What to know about retatrutide